The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
Dapagliflozin is one of the SGLT-2 inhibiters. Recent clinical trials have demonstrated that
SGLT-2 inhibitors are effective for treating heart failure. The DAPA-HF clinical trial has
demonstrated that the effects of empagliflozin and dapagliflozin improve renal outcomes and
reduce all-cause and cardiovascular death in patients with HFrEF[1]. However, its effect on
myocardial infarction, the most common disease leading to death in the population, has not
been evaluated sufficiently. A meta-analysis has demonstrated that compared with the control,
SGLT2 inhibitor is associated with a reduction in the incidence of major adverse
cardiovascular events (MACEs), myocardial infarction, cardiovascular mortality and all-cause
mortality[2]. It seems that dapagliflozin might be effective for patients with acute
myocardial infarction based on these studies. Thus, this study aims to evaluate the effect of
dapagliflozin on short-term prognosis in patients with acute myocardial infarction compared
to placebo.
1. Faiez Zannad, João Pedro Ferreira, Stuart J Pocock et el. SGLT2 inhibitors in patients
with heart failure with reduced ejection fraction: a meta-analysis of the
EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829.
2. Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang et el. Effects of SGLT2 inhibitors on
cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine
(Baltimore). 2019 Dec;98(49):e18245.